Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

480.52
+4.470.94%
Post-market: 481.000.4800+0.10%18:10 EST
Volume:219.91K
Turnover:105.41M
Market Cap:20.69B
PE:18.22
High:482.27
Open:477.28
Low:470.76
Close:476.05
52wk High:519.99
52wk Low:266.98
Shares:43.06M
Float Shares:41.99M
Volume Ratio:0.91
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):26.38
EPS(LYR):24.64
ROE:20.04%
ROA:13.14%
PB:3.14
PE(LYR):19.50

Loading ...

Earning Preview: United Therapeutics Q4 revenue is expected to increase by 10.66%, and institutional views are predominantly bullish

Earnings Agent
·
Feb 18

United Therapeutics EVP and General Counsel Paul A. Mahon Disposes of Common Shares

Reuters
·
2 hours ago

United Therapeutics President and COO Michael Benkowitz Disposes of Common Shares

Reuters
·
Yesterday

Director Jan Malcolm Reports Disposal of United Therapeutics Common Shares

Reuters
·
Feb 18

United Therapeutics: Buy Rating Backed by De-Risked IPF Phase 3 and Underappreciated PAH Upside Beyond Tyvaso Noise

TIPRANKS
·
Feb 17

United Therapeutics Advances IPF Program With TETON-2 And PROLIFIC Milestones

Simply Wall St.
·
Feb 12

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results

Reuters
·
Feb 11

United Therapeutics President and COO Michael Benkowitz Reports Disposal of Common Shares

Reuters
·
Feb 11

United Therapeutics Nears Key Data Milestone With Completed TETON-1 IPF Trial

TIPRANKS
·
Feb 11

Assessing United Therapeutics (UTHR) Valuation After Positive MiroliverELAP Phase 1 Safety And Survival Data

Simply Wall St.
·
Feb 06

United Therapeutics EVP & General Counsel Paul A. Mahon Reports Disposal of Common Shares

Reuters
·
Feb 06

United Therapeutics Director Jan Malcolm Reports Sale of Common Shares

Reuters
·
Feb 04

United Therapeutics President and COO Michael Benkowitz Reports Disposal of Common Shares

Reuters
·
Feb 04

United Therapeutics President and COO Michael Benkowitz Reports Disposal of Common Shares

Reuters
·
Jan 29

United Therapeutics Says Its Experimental Liver Assist Device Met Primary Goal in Phase 1 Study

MT Newswires Live
·
Jan 26

BRIEF-United Therapeutics Announces Positive Results From Phase 1 Study Of Miroliverelap In Patients With Acute Liver Failure

Reuters
·
Jan 26

United Therapeutics Announces Positive Results From Phase 1 Study of Miroliverelap® in Patients With Acute Liver Failure

THOMSON REUTERS
·
Jan 26

United Therapeutics Corp - Study Met Primary Endpoint of Survival During Treatment

THOMSON REUTERS
·
Jan 26

United Therapeutics Corp - No Unexpected Serious Adverse Events Reported

THOMSON REUTERS
·
Jan 26

Assessing United Therapeutics (UTHR) Valuation After Recent Share Price Swings

Simply Wall St.
·
Jan 25